News from NYU Langone Health
I’m a doctor — the 2 things women should do in every decade to stay healthy
New York Post
In an article, Caren F. Behar, MD, co-director of the Mignone Women’s Health Collaborative and medical director of the Joan H. Tisch Center for Women’s Health at NYU Langone Health, outlines key health recommendations for women through each decade of life. She advises women in their 20s to establish care with a doctor and build healthy habits. For the 30s, she highlights family planning and sexual health. Dr. Behar recommends yearly mammograms starting at 40 and first colonoscopies at 45. For later decades, she discusses vaccines, menopause management, blood pressure monitoring, and maintaining mental, physical, and social activity.
Also reporting was: MSN
4/13/2026
The hidden cause of heart disease is inflammation
Scientific American
A growing body of research suggests chronic inflammation is a primary culprit in cardiovascular disease, a view supported by Kathryn Moore, PhD, director of the Cardiovascular Research Center at NYU Grossman School of Medicine, who calls it 'a disease of inflammation.' The article details how the immune system's overreaction to cholesterol crystals in arteries can lead to plaque buildup, heart attacks, and strokes. While cholesterol-lowering statins also reduce inflammation, researchers are now testing dedicated anti-inflammatory drugs like colchicine to further decrease cardiac risk, though clinical trial results have been mixed, prompting further investigation into more targeted therapies.
4/14/2026
Sofetabart Mipitecan Hits 50% Response Rate in Platinum-Resistant Ovarian Cancer
Targeted Oncology
Investigators from the Laura & Isaac Perlmutter Cancer Center at NYU Langone Health reported phase 1a results showing FRα-targeted ADC sofetabart mipitecan achieved a 50% objective response rate in 104 patients with recurrent platinum resistant high grade serous ovarian cancer, with activity across FRα expression levels and 73% of responders still on therapy at 30 July 2025. Safety lacked keratopathy and showed low-grade neuropathy and alopecia, with grade ≥3 anemia 25% and neutropenia 24%. Based on these data, FDA granted breakthrough therapy designation. A global phase 3 FRAmework 01 trial is underway.
4/13/2026
New Obesity Medication Guidance: Will It Reduce Stigma?
Medscape
Three leading obesity organizations have issued new guidance on the pharmacological treatment of obesity, calling for an end to the stigma surrounding the disease. While experts view this as a positive step, they believe change will not be immediate. The guidance emphasizes that recommended medications are safe and effective for long-term use. In the article, Rachel Goldman, PhD, clinical assistant professor in the Department of Psychiatry at NYU Grossman School of Medicine, advises reframing the medications as medical treatments rather than weight-loss drugs to help reduce stigma, which she notes stems from deeply ingrained societal beliefs.
4/13/2026
Sofetabart Mipitecan Displays Antitumor Activity in Recurrent Platinum-Resistant HGSOC
OncLive
Data from a phase 1a trial showed the investigational drug sofetabart mipitecan was safe and effective for patients with recurrent platinum-resistant high-grade serous ovarian cancer. Presenting author Bhavana Pothuri, MD, professor of obstetrics and gynecology, and medical director of the Clinical Trials Office at Perlmutter Cancer Center, noted the drug showed promising clinical activity across all FRα expression levels. The treatment had an overall response rate of 50% and was well-tolerated, even in heavily pre-treated patients. The FDA has since granted the drug breakthrough therapy designation based on these findings.
4/13/2026
Extreme Side Effects Followed Overdose of Unapproved Weight-Loss Drug
MedPage Today
A case report details a 32-year-old man who experienced severe side effects, including intractable diarrhea and acute kidney injury, after overdosing on an unapproved weight-loss drug purchased online. The incident highlights the risks of unregulated, direct-to-consumer peptides, about which the FDA has issued warnings. Priya Jaisinghani, MD, an endocrinologist and assistant professor in the Department of Medicine at NYU Langone Health, advised that clinicians should proactively ask patients where they are obtaining medications and counsel them on the dangers of non-FDA-approved agents, stressing that the risks of unregulated online sales must not be overlooked.
4/13/2026
81 health systems ranked by annual revenue
Becker's Hospital Review
A ranking of 81 health systems by annual revenue for the 12 months ending December 31, 2025, places NYU Langone Health at number 24 with $15.4 billion. The report notes that revenue growth continued across the hospital industry, driven by stronger patient volumes and improved payment rates. Several New York-based competitors were also ranked, including Northwell Health at number 12 with $22.6 billion, Mount Sinai Health System at number 31 with $11.9 billion, and Montefiore at number 44 with $8.8 billion. NYC Health + Hospitals was ranked 22nd with $15.9 billion.
4/13/2026
Oprah Daily
Anticipatory grief is the process of grieving a person or situation before the loss has occurred. Thea Gallagher, PsyD, clinical assistant professor and director of Wellness Programs in the Department of Psychiatry at NYU Langone Health, notes that everyone grieves differently and may not experience the stages of grief in a linear way. The process can serve as a coping mechanism to prepare for an expected loss, often involving feelings of sadness, anger, anxiety, and fear. Experts advise allowing oneself to experience these emotions, building a support system, and seeking counseling to help focus on the present.
4/13/2026
Jonathan Kruskal and Douglas Katz Receive 2026 ARRS Gold Medals
Applied Radiology
The American Roentgen Ray Society awarded its 2026 Gold Medal to Douglas S. Katz, MD, vice chair for clinical research and education in the Department of Radiology at NYU Langone Hospital—Long Island, and Jonathan B. Kruskal of Harvard Medical School. The award recognizes distinguished contributions to radiology. Dr Katz, who is also a professor at NYU Long Island School of Medicine, is a leading figure in emergency and abdominal imaging and has authored or coauthored more than 1,000 publications and abstracts.
4/13/2026
Us Weekly
Model Brooks Nader and her sisters will embark on a polar expedition to the Arctic Circle in April to support women's health research. The initiative, a partnership with the Space Prize Foundation, the University of Arizona, and NYU Langone Health, will study how extreme conditions affect women's hormonal balance, sleep, and physiology. Experts from NYU Langone Health, including Moriah E. Thomason, PhD, the Barakett Professor of Child and Adolescent Psychiatry and vice chair of research, Department of Child and Adolescent Psychiatry, and Katharina Schultebraucks, PhD, associate professor in the Department of Psychiatry at NYU Grossman School of Medicine, will contribute behavioral, neurological, and stress-related analysis for the project.
Also reporting was: Lexington Herald-Leader, The News & Observer, Wichita Eagle, San Luis Obispo Tribune, The Olympian, The Bellingham Herald, Rock Hill Herald, The Modesto Bee, Bradenton Herald, The Charlotte Observer, The State, The Sun News, Belleville News-Democrat, Tacoma News Tribune, Fresno Bee, Kansas City Star, The Telegraph (Macon), Idaho Statesman, Merced Sun-Star, Miami Herald, Fort Worth Star-Telegram, Columbus Ledger-Enquirer, Centre Daily Times, Sun Herald, The Sacramento Bee, Tri-City Herald, The Island Packet
4/13/2026
When Heartburn Isn’t Harmless: Understanding the Link Between GERD and Esophageal Cancer
CURE Magazine
In recognition of Esophageal Cancer Awareness Month, experts are raising awareness about the risks of persistent heartburn. Costas Bizekis, MD, a thoracic surgeon at NYU Langone Health, explained how chronic GERD can damage the esophagus, leading to inflammation and potentially cancerous cell changes. Dr. Bizekis noted that long-standing reflux can cause Barrett’s esophagus, a precancerous condition. For patients with persistent symptoms despite medication, he mentioned that minimally invasive surgical procedures can help reduce reflux and control symptoms, emphasizing that ongoing heartburn should not be ignored.
4/13/2026
GLP-1 Medications Physician Perspectives: What Endocrinologists and PCPs Are Really Saying in 2026
Top Doctor Magazine
The rapid increase in GLP-1 medication prescriptions has created significant clinical challenges for physicians regarding ownership, telehealth prescribing, and ethical boundaries for cosmetic use. The article notes a 700% rise in prescriptions for non-diabetic patients from 2019 to 2023. A key tension is the debate over whether endocrinologists or primary care providers should manage these patients. Michael Weintraub, MD, endocrinologist and clinical assistant professor in the Department of Medicine at NYU Grossman School of Medicine, highlights a competency gap between obesity specialists and PCPs. The piece also addresses concerns about fragmented care from telehealth providers and the need for better training and cross-specialty coordination.
4/13/2026
9 Foods With More Protein Than Steak
Vogue
This article highlights nine foods with high protein content as alternatives to beef amid rising prices. Among the suggestions is high-protein yogurt, with Heather Hodson Py, RD, CDN, a registered dietitian at the Center for the Prevention of Cardiovascular Disease at NYU Langone Heart, noting that Greek yogurt typically has significantly more protein and fewer carbohydrates than regular yogurt. Other alternatives discussed include steelhead trout, smoked salmon, dried seaweed, pork, tuna, chicken, peanuts, and cheddar cheese. The piece advises a holistic approach to diet, considering fiber and other nutrients in addition to protein.
4/13/2026
UroToday
Researchers across nine institutions, including NYU Langone Health, reported long-term outcomes from the SHARP consortium pooling 440 men with high-risk localized prostate cancer treated with SBRT over a median 60.4 months. Five-year biochemical recurrence and distant metastasis rates were 22% and 9.2%. Intensified therapy (≥12 months androgen deprivation plus ≥8 Gy/fraction) reduced recurrence (HR 0.38) and metastasis (HR 0.43), with grade ≥2 genitourinary and gastrointestinal toxicity of 23% and 10%. Findings support SBRT in shared decision-making. Epub ahead of print on 10 April 2026.
4/14/2026
Person functionally cured of HIV after bone marrow transplant from sibling
Scientific American
A 63-year-old man has been functionally cured of HIV after receiving a bone marrow transplant from his brother, who has a rare genetic mutation that confers resistance to the virus. A study in Nature Microbiology showed the donor cells replaced the recipient's bone marrow cells. While this is a significant development, the treatment is not yet widely available due to its risks. Jingmei Hsu, MD, an oncologist at NYU Langone Health's Perlmutter Cancer Center and deputy director of the Transplantation and Cellular Therapy Program, who was not part of the study, noted that this procedure is only for patients with other malignancies requiring a transplant because it is too risky compared to standard antiretroviral therapy.
4/13/2026
Novel study shows impact of staph prevention measures in NICU
Healio
A new study using genome sequencing found that weekly screenings and targeted decolonization with an antibiotic ointment and antiseptic wash significantly reduced the spread of Staphylococcus aureus in the NICU at Tisch Hospital. Researchers, including lead author Sarah Hochman, MD, section chief of infectious diseases at Tisch Hospital and assistant professor of medicine at NYU Grossman School of Medicine, determined that treating 12 infants prevented one transmission event. The findings, presented at the Society for Healthcare Epidemiology of America’s annual conference, demonstrate the direct impact of these infection-prevention measures in a high-risk patient population.
4/13/2026
HealthCentral
In an article about GLP-1 medications, Melanie R. Jay, MD, director of the NYU Langone Comprehensive Program on Obesity, explains that the body is evolutionarily designed to resist weight loss. She notes that these drugs are successful because they target the biological factors driving this resistance. Dr. Jay adds that GLP-1s act on the brain's systems to suppress hunger, boost fullness, and dull the reward response from highly palatable foods. She also cautions that real-world weight loss results are often lower than those seen in clinical trials.
4/13/2026
